公开(公告)号：US20060165706A1

公开(公告)日：2006-07-27

申请号：US11321444

申请日：2005-12-29

申请人： Beatriz Carreno ,  Clive Wood ,  Katherine Turner ,  Mary Collins ,  Gary Gray ,  Donna Morris ,  Denise O'Hara ,  Paul Hinton ,  Naoya Tsurushita

发明人： Beatriz Carreno ,  Clive Wood ,  Katherine Turner ,  Mary Collins ,  Gary Gray ,  Donna Morris ,  Denise O'Hara ,  Paul Hinton ,  Naoya Tsurushita

IPC分类号： A61K39/395 ,  C07K16/46

CPC分类号： A61K51/1027 ,  A61K47/6827 ,  A61K47/6829 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/34

摘要： The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.

公开(公告)号：US20050014934A1

公开(公告)日：2005-01-20

申请号：US10822300

申请日：2004-04-09

申请人： Paul Hinton ,  Naoya Tsurushita ,  J. Tso ,  Maximiliano Vasquez

发明人： Paul Hinton ,  Naoya Tsurushita ,  J. Tso ,  Maximiliano Vasquez

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/08 ,  C07K16/24 ,  C07K16/28 ,  C07K16/44

CPC分类号： C07K16/249 ,  C07K16/00 ,  C07K16/082 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/732

摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.

公开(公告)号：US20050032114A1

公开(公告)日：2005-02-10

申请号：US10687118

申请日：2003-10-15

申请人： Paul Hinton ,  Naoya Tsurushita ,  J. Tso ,  Maximiliano Vasquez

发明人： Paul Hinton ,  Naoya Tsurushita ,  J. Tso ,  Maximiliano Vasquez

IPC分类号： C07K16/00 ,  C07K16/08 ,  C07K16/24 ,  C07K16/28 ,  G01N33/53 ,  C07H21/04 ,  C12N5/06

CPC分类号： C07K16/082 ,  C07K16/00 ,  C07K16/249 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/732

摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.

公开(公告)号：US20050226864A1

公开(公告)日：2005-10-13

申请号：US10966673

申请日：2004-10-15

申请人： Paul Hinton ,  Naoya Tsurushita

发明人： Paul Hinton ,  Naoya Tsurushita

IPC分类号： A61K39/395 ,  C07K14/54 ,  C07K14/705 ,  C07K14/715 ,  C07K16/00 ,  C07K16/08 ,  C07K16/24 ,  C07K16/28 ,  C07K16/44

CPC分类号： C07K14/7151 ,  C07K14/5437 ,  C07K14/70528 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/30

摘要： The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.

摘要翻译： 本发明提供了修饰的Fc融合蛋白，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一种不同于此的氨基酸取代 存在于未修饰的Fc融合蛋白中，从而与未修饰的Fc融合蛋白相比，改变了FcRn的结合亲和力和/或血清半衰期。

公开(公告)号：US20070031408A1

公开(公告)日：2007-02-08

申请号：US11581945

申请日：2006-10-16

申请人： William Olson ,  Paul Maddon ,  Naoya Tsurushita ,  Paul Hinton ,  Maximillano Vasquez

发明人： William Olson ,  Paul Maddon ,  Naoya Tsurushita ,  Paul Hinton ,  Maximillano Vasquez

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/10

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76

摘要： The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmic designated pVgl:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.

摘要翻译： 本发明涉及抗CCR5抗体，其包含（i）两条轻链，每条轻链包含命名为pVK：HuPRO14O-VK（ATCC保藏号PTA-4097）的质粒的表达产物，和（ii）两条重链 每个重链包含称为pVgl：HuPRO140HG2-VH（ATCC保藏号PTA-4098）或质粒命名为pVgl：HuPRO140（mutB + D + I）-VH（ATCC保藏号PTA-4099）的质粒的表达产物 ）或其与人细胞表面上的CCR5结合的片段。

公开(公告)号：US07365168B2

公开(公告)日：2008-04-29

申请号：US11102621

申请日：2005-04-08

申请人： Paul Hinton ,  Naoya Tsurushita ,  J. Yun Tso ,  Maximiliano Vasquez

发明人： Paul Hinton ,  Naoya Tsurushita ,  J. Yun Tso ,  Maximiliano Vasquez

IPC分类号： C12P21/08 ,  C07K1/00

CPC分类号： C07K16/00 ,  C07K16/082 ,  C07K16/249 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/732

摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.

公开(公告)号：US20050276799A1

公开(公告)日：2005-12-15

申请号：US11102621

申请日：2005-04-08

申请人： Paul Hinton ,  Naoya Tsurushita ,  J. Tso ,  Maximiliano Vasquez

发明人： Paul Hinton ,  Naoya Tsurushita ,  J. Tso ,  Maximiliano Vasquez

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/08 ,  C07K16/24 ,  C07K16/28 ,  C07K16/44

CPC分类号： C07K16/00 ,  C07K16/082 ,  C07K16/249 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/732

摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.

摘要翻译： 本发明提供IgG类型的修饰抗体，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一个不同于 其存在于未修饰的抗体中，从而与未修饰的抗体相比改变对FcRn的结合亲和力和/或血清半衰期。

公开(公告)号：US20090155262A1

公开(公告)日：2009-06-18

申请号：US12284137

申请日：2008-09-18

申请人： David S. F. Young ,  Helen P. Findlay ,  Susan E. Hahn ,  Luis A. G. da Cruz ,  Daad Sayegh ,  Kristian Rogers ,  Shankar Kumar ,  Paul Hinton

发明人： David S. F. Young ,  Helen P. Findlay ,  Susan E. Hahn ,  Luis A. G. da Cruz ,  Daad Sayegh ,  Kristian Rogers ,  Shankar Kumar ,  Paul Hinton

IPC分类号： A61K39/395 ,  C07K16/00 ,  C12N5/08 ,  A61P35/00

CPC分类号： G01N33/57492 ,  A61K47/6849 ,  A61K47/6851 ,  A61K51/1027 ,  A61K51/1045 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/92 ,  G01N33/56966 ,  G01N33/5743 ,  G01N2333/70596

摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。

公开(公告)号：US20070025912A1

公开(公告)日：2007-02-01

申请号：US11362452

申请日：2006-02-24

申请人： David Young ,  Helen Findlay ,  Susan Hahn ,  Luis da Cruz ,  Daad Sayegh ,  Kristian Rogers ,  Shankar Kumar ,  Paul Hinton

发明人： David Young ,  Helen Findlay ,  Susan Hahn ,  Luis da Cruz ,  Daad Sayegh ,  Kristian Rogers ,  Shankar Kumar ,  Paul Hinton

IPC分类号： A61K51/00 ,  A61K39/395 ,  C07K16/46 ,  C07K16/30

CPC分类号： G01N33/57492 ,  A61K47/6849 ,  A61K47/6851 ,  A61K51/1027 ,  A61K51/1045 ,  A61K2039/505 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/92 ,  G01N33/56966 ,  G01N33/5743 ,  G01N2333/70596

摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。

公开(公告)号：US20050142131A1

公开(公告)日：2005-06-30

申请号：US10497475

申请日：2002-04-26

申请人： Paul Hinton ,  Maximiliano Vasquez

发明人： Paul Hinton ,  Maximiliano Vasquez

IPC分类号： C07K16/18 ,  C12N5/02 ,  A61K39/395 ,  C07K16/44

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24 ,  Y02A50/407

摘要： Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed closed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.

摘要翻译： 公开了保留小鼠10D5的结合特性的小鼠抗体10D5的人源化形式。 还公开封闭的是制备人源化抗体的方法，用于制备人源化抗体的中间体，包括核苷酸序列，载体，转化的宿主细胞，以及使用人源化抗体治疗，预防，缓解，逆转或以其他方式改善症状或 病理学或两者，与唐氏综合征或临床前或临床阿尔茨海默病或脑淀粉样血管病相关。